OncoPrecision Corporation, a translational therapeutics company developing novel antibody-based cancer therapies, announced on Monday that data from its development candidate, ONC001, has been selected for an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled from 6-9 December 2025 in Orlando, Florida.

ONC001, a first-in-class antibody-drug conjugate (ADC), is designed to target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukaemia, including highly resistant subsets. It was developed using OncoPrecision's proprietary discovery engine, which integrates large-scale, patient-derived biology and AI-enhanced high-throughput screening to reveal the most actionable cellular vulnerabilities.

Dr. Gastón Soria, co-founder and chief scientific officer, is to present the preclinical data, which will show selective engagement of patient-derived CMML and AML cells, robust activity in samples resistant to present standard-of-care therapies, and compelling in vivo efficacy across heterotopic and orthotopic models.

Tarek Zaki, co-founder and CEO of OncoPrecision, said: "The selection of ONC001 for an oral presentation at ASH underscores the strength of this fundamentally new therapeutic approach. ONC001 is designed to specifically target resistance mechanisms that drive certain aggressive blood cancers, offering a new way to overcome common treatment failures. We look forward to sharing this data with the global haematology community and to continuing discussions with prospective development and strategic partners."